

Google, DexCom to jointly work on diabetes management

12 August 2015 | News | By BioSpectrum Bureau

Google, DexCom to jointly work on diabetes management



DexCom, a leader in continuous glucose monitoring (CGM) for people with diabetes, has announced that it has entered into an agreement with the life sciences team at Google to jointly develop a series of next-generation CGM products that are designed to be smaller and less expensive than existing technologies.

These new products will incorporate Google's miniaturized electronics platform with DexCom's best-in-class sensor technology. This collaboration also provides an opportunity to better utilize the data generated by these CGM products to significantly improve the outcomes and reduce the costs associated with diabetes care.

"This partnership has the potential to change the face of diabetes technology forever," said Mr Kevin Sayer, president and chief executive officer of DexCom. He added, "Working together, we believe we can introduce products that will move us beyond our core Type 1 business to become the standard of care for all people living with diabetes."

Mr Andrew Conrad, head of the life sciences team at Google said, "We are committed to developing new technologies that will help move health care from reactive to proactive. This collaboration is another step towards expanding monitoring options and making it easier for people with diabetes to proactively manage their health."

Initial products to be developed under the agreement will focus on minimizing both the cost and size of CGM body worn components. The products will be designed to be disposable, and will be intended for use across all diabetes markets. The goal is to empower more people to control their diabetes with real-time and actionable information by developing a low-cost, small, bandage-sized sensor that is connected to the cloud. By addressing these needs, we believe we will have the platform that can replace finger sticks and become the standard of care.

DexCom retains all sales and distribution rights of the products developed under this agreement. DexCom is also obligated to pay an initial upfront payment and milestone payments during development, and revenue-based royalties once these products are launched and have achieved a certain level of revenue.